Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADUHELM in Early Alzheimer's Disease (China CTR20232067)
CTR20232067Phase 3Terminated
- Sponsor
- Biogen
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of aducanumab in Alzheimer's disease (AD), sponsored by Biogen. Started Jul 2023; status: terminated.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20232067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232067.